Hevolution Foundation, a non-profit organisation that provides grants and early-stage investments to incentivise research and entrepreneurship in healthspan science, has appointed Dr William Greene as Chief Investment Officer (CIO).
The new CIO will oversee all aspects of Hevolution Foundation’s investment strategy, planning, analysis and execution.
Over the course of his career, Dr Greene has been a life sciences company founder, investor, operating executive and clinician.
Prior to joining Hevolution as an advisor in May 2022, Dr Greene served as CEO of Fountain Therapeutics – a longevity biotechnology company founded by Stanford Neurology professor Thomas Rando, MD, PhD.
Mehmood Khan, MD, Chief Executive Officer, said:
“After conducting a thorough search process, and working closely with Bill for over six months, I could not be more pleased to officially welcome him to Hevolution.
“Since our unveiling over the summer we have announced a number of promising collaborations and grants programs.
“In 2023 and beyond we look forward to building on this momentum, not only on the grants side of our operation but with some key investments and impact-focused initiatives, led by Bill and his team.”
Prior to Fountain Therapeutics, Dr Greene was CEO of Iconic Therapeutics, where he led the start-up through discovery and development through to pharma partnerships and a successful sale of the company.
Dr Greene commented:
“Hevolution Foundation and its bold mission speak to what has driven me throughout my career: a desire to tackle the most pressing problems, work with great teams, and use science and medicine to drive positive change.
“I am eagerly anticipating driving Hevolution’s investment strategy in partnership with the scientific team and the rest of the organization as we expand internationally and seek to play a global role in meeting one of humanity’s greatest challenges: unhealthy ageing.”
